Showing results (151-160 of 313) with videos related to

Sort By:
Pageof 32
Blood|September 16, 2011
Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemiaSteven M Kornblau, Yi Hua Qiu, Nianxiang Zhang, et al.
Blood|June 15, 2011
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemiaXavier C Badoux, Michael J Keating, Xuemei Wang, et al.
Blood|September 1, 2005
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)Varsha Gandhi, John M Kilpatrick, William Plunkett, et al.
Blood|January 20, 2011
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLLXavier C Badoux, Michael J Keating, Xuemei Wang, et al.
Haematologica|August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesGautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylateJorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndromeHagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, et al.
Cancer|August 12, 2003
Phase II study of alemtuzumab in chronic lymphoproliferative disordersAlessandra Ferrajoli, Susan M O'Brien, Jorge E Cortes, et al.
Cancer Research|April 23, 2009
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cellsStefan Faderl, Ashutosh Pal, William Bornmann, et al.
Cancer|May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disordersJorge Cortes, Francis Giles, Susan O'Brien, et al.
Pageof 32